9/24/2023 0 Comments Proteus sensors![]() ![]() But this application furthers the products use in clinical trials in Europe. The Proteus ingestible event marker is approved in the EU and the United States for use as a medical device. ![]() Specifically, Proteus requested the EMA to consider the use of its technology “as a ‘qualified method’ for measuring adherence and associating relevant physiologic and behavioral parameters, such as indications of therapeutic response.” Public consultation began September 15, and ends on October 26. In early August, the EMA issued a draft qualification opinion on “Ingestible sensor system for medication adherence as biomarker for measuring patient adherence to medication in clinical trials.”
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |